Aynechi Tiba 4
4 · MBX Biosciences, Inc. · Filed Sep 17, 2024
Insider Transaction Report
Form 4
Aynechi Tiba
Director
Transactions
- Conversion
Series B Convertible Preferred Stock
2024-09-16−16,666,666→ 0 total(indirect: By Norwest Venture Partners XVI, LP)→ Common Stock (1,386,335 underlying) - Purchase
Common Stock
2024-09-16$16.00/sh+750,000$12,000,000→ 2,136,335 total(indirect: By Norwest Venture Partners XVI, LP) - Conversion
Common Stock
2024-09-16+1,386,335→ 1,386,335 total(indirect: By Norwest Venture Partners XVI, LP)
Footnotes (3)
- [F1]Each share of Series B Convertible Preferred Stock (the "Preferred Stock") was convertible into Common Stock on a one-for-12.0221 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on September 16, 2024. The Preferred Stock had no expiration date.
- [F2]The securities are directly held by Norwest Venture Partners XVI, LP ("NVP XVI"). Genesis VC Partners XVI, LLC ("Genesis XVI") is the general partner of NVP XVI and NVP Associates, LLC ("NVP Associates") is the managing member of Genesis XVI. The Reporting Person, as an officer of NVP Associates and director of the Issuer, may be deemed to share voting and dispositive power over the shares held by NVP XVI and disclaims beneficial ownership of such securities except to the extent of her pecuniary interest therein.
- [F3]Reflects shares purchased in the Issuer's initial public offering.